Quantcast

Latest Hyperuricemia Stories

2011-05-19 07:30:00

HAYWARD, Calif., May 19, 2011 /PRNewswire/ -- Metabolex, Inc., a biopharmaceutical company focused on the discovery and development of proprietary new medicines for the treatment of metabolic diseases, announced today that it has initiated a Phase 2 clinical trial of arhalofenate (MBX-102), its product candidate for the management of hyperuricemia in patients with gout. This randomized, double-blind, placebo-controlled study will evaluate the safety and urate-lowering activity of 400 and...

2011-05-17 10:00:00

CLEVELAND, May 17, 2011 /PRNewswire/ -- A new survey from the nonprofit Gout & Uric Acid Education Society (GUAES) highlights an alarming awareness gap among Americans regarding the risk factors for gout, a chronic, potentially disabling form of arthritis which now affects an estimated 8.3 million Americans.(1) Among the survey findings are that only one in 10 Americans correctly cited cardiovascular disease as a risk factor for gout, while only one in three Americans correctly...

2011-05-04 17:23:00

EAST BRUNSWICK, N.J., May 4, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that it has, through its wholly owned subsidiary, Savient Pharma Ireland Limited, delivered via courier to the European Medicines Agency (EMA) and the assigned co-rapporteurs, the Marketing Authorization Application (MAA) for KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Currently there are no EMA...

2011-04-25 08:00:00

SAN DIEGO, April 25, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that additional data from its completed Phase 2b study (Study 203) evaluating lesinurad in combination with allopurinol in gout patients not adequately responding to allopurinol alone will be presented at the Annual European Congress of Rheumatology hosted by the European League Against Rheumatism (EULAR) on May 26, 2011 in London, UK. The Company will also present additional data from a...

2011-04-06 09:15:00

SAN DIEGO, April 6, 2011 /PRNewswire/ -- Getting the word out about preventing and treating gouty arthritis has new urgency with the number of Americans suffering from this form of arthritis now topping the 8 million mark. If left untreated, gout can be disabling. Gout is also associated with other serious health conditions, making it a complex diagnosis and treatment challenge for physicians. In addition to the core patient demographic of men age 40 plus, post-menopausal women are at...

2011-01-06 15:00:00

SAN DIEGO, Jan. 6, 2011 /PRNewswire/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced positive, preliminary, top-line results from its Phase 2b study of RDEA594 in combination with the current standard of care for the treatment of gout, allopurinol. Allopurinol currently accounts for greater than 90% of the unit sales of chronic gout prescription medications; however, in controlled trials, only 30-40% of gout patients respond adequately to allopurinol as defined by the...

2010-11-29 06:26:00

SHENYANG, China, Nov. 29, 2010 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq: SSRX) ("3SBio" or "Company"), a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced that is has acquired worldwide rights of pegsiticase for all indications from EnzymeRx for a total consideration of US$6.25 million. Pegsiticase (Uricase-PEG 20) is a pegylated recombinant uricase derived from Candida utilis,...

2010-11-08 06:00:00

SAN DIEGO, Nov. 8, 2010 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced positive results from two clinical studies of RDEA594 in combination with currently marketed drugs for the treatment of gout patients, febuxostat (Uloric®) and allopurinol. RDEA594, Ardea's lead product candidate for the chronic management of hyperuricemia and gout, is an orally administered compound that inhibits the URAT1 transporter, a biological mechanism that...

2010-09-14 17:09:00

EAST BRUNSWICK, N.J., Sept. 14 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the U.S. Food and Drug Administration (FDA) has approved KRYSTEXXA(TM) (pegloticase), a PEGylated uric acid specific enzyme indicated for the treatment of chronic gout in adult patients refractory to conventional therapy. Chronic gout that is refractory to conventional therapy occurs in patients who have failed to normalize serum uric acid and whose signs and...

2010-09-13 16:05:00

ATLANTA and DEERFIELD, Ill., Sept. 13 /PRNewswire/ -- The Arthritis Foundation and Takeda Pharmaceuticals North America, Inc., today announced the launch of a new educational campaign, Gout Living, to help increase understanding and encourage better management of gout. The campaign, which includes the first-ever gout public service announcements (PSAs), aims to encourage those living with the disease to be proactive about their health. The PSAs, which will be available via television, radio...


Latest Hyperuricemia Reference Libraries

45_cf9ebc73b3f1a13d4b11b52db1780092
2008-05-22 12:47:07

The Dalmatian is a coach dog which is easily recognized for its unique spotted coat. This ancient breed has been used as a guard dog, bird dog, trail hound, retriever, and most importantly a coach or carriage dog. The Dalmatian was once used to run in attendance on a coach. This ability was eventually transferred to its career as a firehouse dog. The Dalmatian once ran in front of horse-drawn fire carts to help clear a path for them as well as guide them to fires. The Dalmatian is a...

More Articles (1 articles) »
Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'